Acta clinica Croatica, Vol. 42 No. 2, 2003.
Original scientific paper
Initial Clinical Experience with Brinzolamide 1% Ophthalmic Suspension (AZOPT ®)
Katia Novak-Lauš
Zdravko Mandić
Renata Iveković
Lovro Bojić
Jadranka Koršić
Mia Zorić-Geber
Abstract
The aim of the study was to assess the intraocular hypotensive effect of 1.0% brinzolamide (b.i.d.) as monotherapy in patients with primary and secondary glaucoma. The six-month study included 2 patients of which 19 completed the study (one patient was excluded due to allergic drug reaction). All patients had previously received local antiglaucoma therapy. Because of local undesired side effects and inadequate control of intraocular pressure they were switched to treatment with 1.0% brinzolamide as monotherapy. Intraocular pressure was measured on the day of therapy introduction, and then at 15 days, one month, three months and six months of therapy. Nineteen patients successfully completed the six-month study. A clinically significant decrease in the intraocular pressure was recorded. The difference in intraocular pressure between the baseline (23.8 ± 2.4), and 15-day (18.2 ± 2.8), one-month (18.2 ± 2.7), three-month (18.5 ± 2.9) and six-month (18.8 ± 3.2) levels was statistically significant (p<0.001). Deviation from the mean values of intraocular pressure was considered as standard deviation. Local side effects such as scratching and pricking were recorded in three patients; however, there were no systemic or other side effects. Results of the study suggested monotherapy with 1.0% brinzolamide (b.i.d.) to be successful in the regulation of intraocular pressure in patients with primary or secondary glaucoma.
Keywords
Carbonic anhydrase inhibitors, therapeutic use; Carbonic anhydrase inhibitors, adverse effects; Glaucoma, drug therapy
Hrčak ID:
14590
URI
Publication date:
2.6.2003.
Visits: 1.394 *